Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies
C Orla Morrissey, Sharon C-A Chen, Tania C Sorrell, Kenneth F Bradstock, Jeffrey Szer, Catriona L Halliday, Nicole M Gilroy, Anthony P Schwarer, Monica A Slavin
Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2011
Awarded by Australian National Health and Medical Research Council
Major funding: Australian National Health and Medical Research Council (Project Grant 331305); Cancer Council New South Wales; Pfizer (Global) and Pfizer (Australia).Minor funding: Centre for Clinical Research Excellence in Infectious Diseases, Royal Melbourne Hospital, Melbourne, VIC, Australia; Centre for Clinical Research Excellence in Infections, Bioethics and Haematological Malignancies, Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia; Merck Sharp & Dohme (Australia) and Gilead Sciences.C.O.M. serves/has served on Advisory Boards for, received investigator-initiated grants from, and given lectures for Gilead Sciences, Pfizer, Merck, Schering Plough, and Orphan Australia. S.C.-A.C., T.C.S., and M.A.S. serve/have served on Advisory Boards for Pfizer, Merck, Gilead, and Schering Plough and have received investigator-initiated grants from Pfizer, Merck, and Gilead. J.S. serves/has served on Advisory Boards for and has received investigator-initiated grants from Gilead Sciences and Pfizer Australia. K.F.B. has served on Advisory Boards for Pfizer, Merck, and Schering Plough and has been a consultant for Pfizer.